MELK and cancer: In addition, a CRISPR/Cas9-focused study that reached similar conclusions to our study, demonstrated that off-target mechanisms contribute to the anticancer effects of OTSSP167 because WT and MELK−/− cancer cell lines were similarly sensitive to OTSSP167 treatment (Lin et al., 2017).